Last edition
News about "Clinical Training Program (CTP) "
Organon Wins FDA Approval to Extend Duration of Use for NEXPLANON
Organon has received US Food and Drug Administration (FDA) approval for a supplemental New Drug Application extending the duration of use of NEXPLANON, its etonogestrel radiopaque contraceptive implant, to up to five years, expanding the product’s earlier three-year indication and offering longer-lasting contraceptive protection.
Clinical Training Program (CTP) | 17/01/2026 | By News Bureau | 273
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy